OakChart

Intellia Therapeutics Inc

NTLAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

11.41+0.24 (2.15%)
2026-11-12 00:27 CET
Market cap
1,567.80 USD m
Revenue, TTM
52.89 USD m
Net income, TTM
-426.14 USD m
Free cash flow, TTM
-358.08 USD m
EPS diluted, TTM
-3.35
P/E
-
Compare

Price

NTLA against its 20, 50 and 200-day averages
2050200beatmissearnings
10.0012.0014.0016.0018.008.2M16.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NTLAclose 11.4120-day 11.7950-day 12.02200-day 12.9911.4152w high

38.3% under the 52-week high of 18.48 on 2 Jul 2026. 52-week low 7.95 on 20 Nov 2025. Last 15 sessions, 31.8% high to low

Volume 0.69× normal · the line is the 50-bar volume average

Profile

NTLA
52-week range, 33% of the way up
7.9518.48

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

IndexRUT
Employees377
IPOMay 06, 2016
Beta1.83
ATR, 14d0.84
Rel volume0.69
Short float33.07%
Insider own4.41%
Inst own102.12%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.60B
Enterprise Value1.36B
Income-426.14M
Sales52.89M
Book/sh4.37
Cash/sh3.38
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees377
IPOMay 06, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S30.28
P/B2.61
P/C3.38
P/FCF-
EV/EBITDA-
EV/Sales25.67
Quick Ratio6.31
Current Ratio6.31
Debt/Eq0.38
LT Debt/Eq0.34
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.35
EPS next Y-2.76
EPS next Q-0.79
EPS this Y12.57%
EPS next Y17.23%
EPS next 5Y22.80%
EPS past 3/5Y14.82% -9.70%
Sales past 3/5Y9.09% 3.13%
EPS Y/Y TTM21.55%
Sales Y/Y TTM-8.07%
EPS Q/Q1.11%
Sales Q/Q-48.03%
EarningsNov 05 BMO
EPS/Sales Surpr.-14.18% -26.47%

Ownership

Insider Own4.41%
Insider Trans-0.78%
Inst Own102.12%
Inst Trans28.68%
ROA-46.63%
ROE-62.60%
ROIC-51.83%
Gross Margin76.86%
Oper. Margin-821.24%
Profit Margin-805.75%
SMA20-3.19%
SMA50-5.09%
SMA200-12.18%
Trades-

Technical

Shs Outstand140.25M
Shs Float134.16M
Short Float33.07%
Short Ratio10.07
Short Interest44.36M
52W High18.48 -38.26%
52W Low7.95 43.52%
Volatility7.88% 7.13%
ATR (14)0.84
RSI (14)46.38
Beta1.83
Rel Volume0.69
Avg Volume4.41M
Volume3,034,355

Performance

Perf Week-7.31%
Perf Month-4.20%
Perf Quarter-3.55%
Perf Half Y-20.10%
Perf YTD26.92%
Perf Year12.08%
Perf 3Y-52.71%
Perf 5Y-91.26%
Perf 10Y-22.91%
Recom2.40
Target Price22.53
Prev Close11.17
Price11.41
Change %2.15%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 06, 2026InitiatedBBarclaysUnderweight$8-29.9%
Jul 16, 2026DowngradeWWolfe ResearchPeer Perform → Underperform$9-21.1%
Mar 02, 2026UpgradeWWilliam BlairMkt Perform → Outperform
Nov 12, 2025DowngradeWWolfe ResearchOutperform → Peer Perform
Nov 11, 2025DowngradeEEvercore ISIOutperform → In-line$8-29.9%
Nov 07, 2025DowngradeJJP MorganNeutral → Underweight$5-56.2%
Oct 28, 2025DowngradeRRBC Capital MktsOutperform → Sector Perform$14+22.7%
Oct 28, 2025DowngradeBBernsteinOutperform → Mkt Perform
Oct 27, 2025DowngradeWWilliam BlairOutperform → Mkt Perform
Oct 27, 2025DowngradeGGuggenheimBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
BEAMBeam Therapeutics Inc2.67B
CRSPCRISPR Therapeutics AG4.44B
EDITEditas Medicine Inc367.33M
PRMEPrime Medicine Inc779.92M
ALNYAlnylam Pharmaceuticals Inc21.41B
IONSIonis Pharmaceuticals Inc4.72B
PHVSPharvaris NV2.40B
BBIOBridgeBio Pharma Inc15.49B
SCTXScribe Therapeutics Inc319.18M
BCRXBiocryst Pharmaceuticals Inc1.97B

Insider trading

latest 14 of 25
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
LEONARD JOHN MPresident and CEONov 02 '26Sale11.999,000107,9101,138,064Nov 03 04:20 PM
LEONARD JOHN MOfficerNov 02 '26Proposed Sale12.609,000113,400Nov 02 04:15 PM
Dube Michael PVP, Chief Accounting OfficerOct 02 '26Sale12.431,86423,17065,022Oct 06 04:05 PM
ELIANA CLARKOfficerOct 05 '26Proposed Sale12.7557,750736,312Oct 05 04:45 PM
LEONARD JOHN MPresident and CEOAug 20 '26Sale12.6019,890250,6141,149,849Aug 24 04:05 PM
LEONARD JOHN MPresident and CEOAug 21 '26Sale13.002,78536,2051,147,064Aug 24 04:05 PM
LEONARD JOHN MOfficerAug 20 '26Proposed Sale12.9522,675293,641Aug 20 04:03 PM
Dulac Edward J IIIEVP, Chief Financial OfficerJul 22 '26Sale11.258,11191,249148,175Jul 24 05:26 PM
Dube Michael PVP, Chief Accounting OfficerJul 01 '26Sale16.782,64144,31666,886Jul 06 05:02 PM
Dulac Edward J IIIEVP, Chief Financial OfficerJul 02 '26Sale18.004,67784,186156,286Jul 06 05:01 PM
EDWARD DULACOfficerJul 02 '26Proposed Sale17.244,67780,631Jul 02 04:32 PM
BASTA JAMESEVP, General CounselMar 02 '26Sale13.781,21116,688156,794Mar 03 04:18 PM
Clark ElianaEVP, Chief Technical OfficerMar 02 '26Sale13.786078,36493,864Mar 03 04:16 PM
LEONARD JOHN MPresident and CEOJan 05 '26Sale9.2134,146314,4851,013,339Jan 07 04:05 PM

Held by

AUM
TickerCompanyAUM
ARKEARK DIET Q3 Buffer ETFAUM: 1.45M
ARKKARK Innovation ETFAUM: 5.97B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
ARKGARK Genomic Revolution ETFAUM: 1.97B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.910-0.797-0.9107.169.7417
2026Q22026-08-06-0.800-0.799-0.7997.6612.9816
2026Q12026-05-11-0.810-0.911-0.81215.0513.8118
2025Q42026-02-26-0.830-0.955-0.82623.0211.9819
2025Q32025-11-06-0.920-1.005-0.92013.7813.9121
2025Q22025-08-07-0.980-1.018-0.97614.2511.8922
2025Q12025-05-08-1.100-1.279-1.10516.6312.7721
2024Q42025-02-27-1.270-1.331-1.26612.878.5525
2024Q32024-11-07-1.340-1.390-1.3449.118.2825
2024Q22024-08-08-1.520-1.217-1.5166.9619.6825
2024Q12024-05-09-1.120-1.366-1.12528.9411.2423
2023Q42024-02-22-1.460-1.439-1.461-1.9212.7424
2023Q32023-11-09-1.380-1.499-1.37911.9913.0523
2023Q22023-08-03-1.400-1.321-1.40313.5912.0824
2023Q12023-05-04-1.170-1.400-1.17512.6111.8324
2022Q42023-02-23-1.400-1.379-1.39613.5711.3327

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.110-2.096-2.10743.1042.08
2020FY-2.400-2.279-2.39857.9966.73
2021FY-3.780-3.604-3.77933.0529.16
2022FY-6.160-6.162-6.16152.1251.90
2023FY-5.420-5.440-5.42136.2850.66
2024FY-5.250-5.312-5.25157.8853.93
2025FY-3.810-3.978-3.81067.6756.58
2026FY--3.331--43.49
2027FY--2.757--115.15
2028FY--1.764--354.84
2029FY-0.808--964.3
2030FY-3.609--1,573

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06152713.747.0070.10
2026Q4S2026-11-05152515.417.0070.10
2026Q4S2026-11-03150116.080.0054.90
2026Q4S2026-10-27151017.060.0069.60
2026Q4S2026-10-21152017.060.0069.60
2026Q4S2026-10-20153017.060.0069.60
2026Q4S2026-09-04153417.060.0069.60
2026Q4S2026-09-03152416.080.0054.90
2026Q4S2026-08-13152416.080.0054.90
2026Q4S2026-08-09151414.970.0054.90
2026Q4S2026-08-07151514.970.0054.90
2026Q4S2026-08-06150514.480.0054.90
2026Q4S2026-07-26150116.450.0054.90
2026Q4S2026-07-25151216.450.0054.90

Estimate history

EPS, annual-1.88-1.982-2.107-2.398-3.779-6.161-5.421-5.251-3.808-3.3467
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.344-1.266-1.105-0.976-0.92-0.826-0.812-0.799-0.909
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual26.11730.43443.10357.99433.05352.12136.27557.87767.67152.89
Period201720182019202020212022202320242025TTM
Sales, quarterly9.11112.87416.62714.24513.78223.01715.0487.6597.163
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual42.38545.22450.19866.23474.48687.10392.997102.03116.317140.254
Period201720182019202020212022202320242025MRQ
Shares, quarterly101.796102.03103.54105.331115.787116.317120.448140.018140.254
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue52.8967.6757.8836.2752.1233.0557.9943.1030.43
Cost of Goods Sold Incl. D&A12.2415.9210.298.987.576.89---
Gross Profit40.6551.7547.5927.3044.5526.16---
Selling, General and Administrative Excl. Other474.97492.74581.86542.59502.71294.01188.27143.88116.84
Research and Development326.73379.09456.03426.09412.41222.92144.10108.4189.11
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-434.33-440.99-534.26-515.29-458.16-267.85-136.58-106.37-90.87
Interest Expense0.610.000.000.000.000.000.000.000.00
Unusual Expense14.510.9032.560.1013.480.000.00--
Net Income Before Taxes-426.14-412.69-519.02-481.19-474.19-267.89-134.23-99.53-85.34
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-426.14-412.69-519.02-481.19-474.19-267.89-134.23-99.53-85.34
Net Income From Continuing Operations-426.14-412.69-519.02-481.19-474.19-267.89-134.23-99.53-85.34
Net Income-426.14-412.69-519.02-481.19-474.19-267.89-134.23-99.53-85.34
EPS (Recurring)-2.97-3.80-5.02-5.42-6.04-3.78-2.40-2.11-1.98
EPS (Basic, Before Extraordinaries)-3.35-3.81-5.25-5.42-6.16-3.78-2.40-2.11-1.98
EPS (Diluted)-3.35-3.81-5.25-5.42-6.16-3.78-2.40-2.11-1.98
EBITDA-422.09-425.07-523.98-506.31-450.59-260.96-130.27-100.78-86.41
Non-Operating Income (Expense)23.3229.2047.8134.20-2.54-0.042.356.835.53
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense62.6980.22154.27134.0591.4047.0119.9015.0917.05
Price To Sales Ratio31.9714.4019.9174.6151.53253.6152.5216.0819.32
Gross Margin76.8676.4782.2375.2685.4779.15---
Operating Margin-821.24-651.67-923.10-1,420.51-879.04-810.37-235.51-246.78-298.58
Net Margin-805.75-609.85-896.77-1,326.51-909.78-810.49-231.46-230.92-280.42
Shares Outstanding140.25116.32102.0393.0087.1074.4966.2350.2045.22
Market Capitalization1,567.801,567.801,187.562,730.532,973.828,799.353,214.00717.10592.67

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue7.167.6615.0523.0213.7814.2416.6312.87
Cost of Goods Sold Incl. D&A1.922.102.206.014.942.502.502.57
Gross Profit5.245.5612.8517.008.8511.7414.1310.31
Selling, General and Administrative Excl. Other127.56118.32113.38115.71120.32121.74128.44146.75
Research and Development81.4280.5078.5386.2792.3394.53105.93114.31
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-122.33-112.76-100.53-98.71-111.48-110.00-114.31-136.45
Interest Expense0.610.000.000.000.000.000.000.00
Unusual Expense10.39-0.330.903.55-3.44-1.348.623.08
Net Income Before Taxes-127.48-106.63-96.23-95.79-101.32-101.25-114.33-128.90
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-127.48-106.63-96.23-95.79-101.32-101.25-114.33-128.90
Net Income From Continuing Operations-127.48-106.63-96.23-95.79-101.32-101.25-114.33-128.90
Net Income-127.48-106.63-96.23-95.79-101.32-101.25-114.33-128.90
EPS (Recurring)-0.86-0.80-0.81-0.80-0.94-0.99-1.05-1.24
EPS (Basic, Before Extraordinaries)-0.91-0.80-0.81-0.83-0.92-0.98-1.10-1.27
EPS (Diluted)-0.91-0.80-0.81-0.83-0.92-0.98-1.10-1.27
EBITDA-120.40-110.66-98.33-92.69-106.54-107.50-111.81-133.88
Non-Operating Income (Expense)5.845.805.216.486.717.408.6010.63
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.4018.0713.4816.7419.6022.0421.8439.62
Price To Sales Ratio31.9737.9522.9815.4033.0818.4116.1520.52
Gross Margin73.1572.5885.3773.8764.1982.4584.9880.07
Operating Margin-1,707.73-1,472.25-668.08-428.86-808.86-772.17-687.48-1,059.86
Net Margin-1,779.77-1,392.27-639.49-416.15-735.19-710.81-687.61-1,001.23
Shares Outstanding140.25140.02120.45116.32115.79105.33103.54102.03
Market Capitalization1,567.802,364.101,514.481,041.311,853.88971.61736.011,187.56

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments449.88601.51912.221,192.62748.69600.07279.73314.06340.68
Short Term Receivables9.478.5236.463.772.032.134.627.5510.47
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets68.3629.8349.6520.4118.5814.325.133.373.68
Total Current Assets527.71639.86998.331,216.80769.30616.52289.48324.98354.83
Net Property, Plant & Equipment123.63246.67148.13161.00100.1155.0637.1317.0615.27
Total Investments and Advances167.35273.82125.23113.75397.571.904.750.000.00
Intangible Assets--------0.00
Other Assets23.4430.6629.2828.5727.482.852.925.286.13
Total Assets842.131,191.021,300.981,520.111,294.46676.32334.28347.31376.24
Short Term Debt Incl. Current Port. of LT Debt26.4820.2518.6016.689.115.705.750.000.00
Accounts Payable20.2514.597.455.159.6510.463.942.712.17
Other Current Liabilities57.1576.0289.16104.72107.0748.1025.9537.8629.19
Total Current Liabilities103.88110.85115.21126.55125.8364.2535.6340.5731.36
Long Term Debt66.85189.9596.75114.0264.9133.6112.630.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.0018.2638.8543.9663.4851.3916.1428.8244.28
Total Liabilities170.73319.06250.81284.53254.22149.2564.4069.3975.64
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity671.39871.961,050.171,235.581,040.24527.07269.88277.92300.60
Total Shareholders Equity671.39871.961,050.171,235.581,040.24527.07269.88277.92300.60
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity671.39871.961,050.171,235.581,040.24527.07269.88277.92300.60
Total Liabilities & Stockholders Equity842.131,191.021,300.981,520.111,294.46676.32334.28347.31376.24
Book Value Per Share5.778.5511.2914.1913.977.965.386.157.09
Tangible Book Value Per Share5.778.5511.2914.1913.977.965.386.157.09
Full-Time Employees377403526598485312270211195
Price to Book Ratio2.561.232.623.248.476.842.732.223.94
Return on Assets-40.60-41.66-34.11-33.69-27.19-26.56-29.21-23.59-20.01
Return on Equity-53.48-54.00-42.10-41.67-34.18-33.69-36.34-29.50-26.46
Return on Invested Capital-55.90-48.88-41.96-35.14-24.24-23.94-35.23-30.71-22.47
Quick Ratio5.085.778.679.616.119.598.128.0111.32
Current Ratio5.085.778.679.616.119.598.128.0111.32

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-426.14-412.69-519.02-481.19-474.19-267.89-134.23-99.53-85.34
Depreciation12.2215.9210.298.987.576.896.315.594.46
Other Funds (Non Cash)75.1775.79147.98130.58187.2058.8820.4811.3716.45
Funds from Operations-338.75-320.98-360.76-341.63-279.41-202.13-107.44-82.58-64.43
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-16.43-73.7511.88-52.45-53.87-22.9057.53-20.663.18
Cash from Operating Activities-355.17-394.74-348.88-394.09-333.29-225.03-49.91-103.24-61.26
Capital Expenditures-2.90-1.13-5.78-13.98-13.56-12.76-3.58-6.79-6.36
Net Assets From Acquisitions0.000.000.000.00-44.830.000.000.00-
Sale of Fixed Assets and Businesses0.360.000.000.000.150.000.000.000.13
Purchase or Sale of Investments16.76229.16131.34-17.36218.55-538.02-210.9031.97-254.56
Purchase of Investments-388.37-322.51-935.57-904.46-429.03-1,023.62-473.70-297.03-254.56
Sale Or Maturity of Investments405.13551.671,066.92887.10647.58485.60262.80329.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities14.21228.03125.57-31.35160.31-550.78-214.4925.18-260.78
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock231.66131.49185.75130.32582.96736.69371.7876.4340.22
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock231.66131.49185.75130.32582.96736.69371.7876.4340.22
Proceedsfrom Stock Options228.15128.18176.90119.80565.79693.57358.6572.2628.55
Issuance or Reduction of Debt, Net73.460.000.000.000.000.000.000.000.00
Change in Long Term Debt73.460.000.000.000.000.000.000.000.00
Issuance of Long Term Debt73.460.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities305.12131.49185.75130.32582.96736.69371.7876.4340.22
Net Change in Cash-35.84-35.22-37.57-295.11409.98-39.12107.38-1.63-281.82
Free Cash Flow-358.08-395.87-354.66-408.07-346.85-237.79-53.50-110.03-67.61
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments474.11437.76375.99449.88511.04459.83
Short Term Receivables7.507.329.139.4711.0511.35
Inventories0.000.000.000.000.000.00
Other Current Assets24.7482.7581.3368.3659.8524.76
Total Current Assets506.35527.83466.45527.71581.94495.94
Net Property, Plant & Equipment226.41101.01113.06123.63138.30151.85
Total Investments and Advances167.60227.88178.22167.35202.11210.72
Other Assets2.200.441.0523.442.9240.38
Total Assets902.56857.16758.78842.13925.27898.89
Short Term Debt Incl. Current Port. of LT Debt20.9823.3419.0926.4827.3826.99
Accounts Payable12.5511.7118.8020.2513.269.80
Other Current Liabilities46.7744.3338.5557.1553.0958.71
Total Current Liabilities80.3179.3976.44103.8893.7395.50
Long Term Debt209.1650.0761.4066.8570.5975.60
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.0012.5412.54
Total Liabilities289.47129.46137.84170.73176.85183.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity613.09727.71620.94671.39748.42715.25
Total Shareholders Equity613.09727.71620.94671.39748.42715.25
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity613.09727.71620.94671.39748.42715.25
Total Liabilities & Stockholders Equity902.56857.16758.78842.13925.27898.89
Book Value Per Share4.375.205.165.776.466.79
Tangible Book Value Per Share4.375.205.165.776.466.79
Full-Time Employees---377--
Price to Book Ratio2.563.282.221.392.541.25
Return on Assets-46.63-45.55-45.23-40.60-42.49-45.94
Return on Equity-62.60-55.44-56.34-53.48-52.11-56.95
Return on Invested Capital-15.50-13.71-14.10-12.97-12.37-12.80
Quick Ratio6.316.656.105.086.215.19
Current Ratio6.316.656.105.086.215.19

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-127.48-106.63-96.23-95.79-101.32-101.25
Depreciation1.922.082.206.014.942.47
Other Funds (Non Cash)24.0417.2913.8519.9915.0819.03
Funds from Operations-101.52-87.27-80.18-69.78-81.31-79.75
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital16.094.15-37.160.494.41-19.87
Cash from Operating Activities-85.43-83.11-117.35-69.28-76.90-99.62
Capital Expenditures-0.89-1.81-0.08-0.13-0.03-0.24
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.270.090.000.000.000.00
Purchase or Sale of Investments62.56-139.8566.3927.66-0.71107.15
Purchase of Investments-53.97-220.39-46.97-67.05-116.65-55.60
Sale Or Maturity of Investments116.5380.54113.3594.71115.94162.75
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities61.94-141.5766.3127.53-0.74106.91
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.00196.1233.571.98114.8614.65
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.00196.1233.571.98114.8614.65
Proceedsfrom Stock Options0.00194.5833.570.00114.7613.41
Issuance or Reduction of Debt, Net73.460.000.000.000.000.00
Change in Long Term Debt73.460.000.000.000.000.00
Issuance of Long Term Debt73.460.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities73.46196.1233.571.98114.8614.65
Net Change in Cash49.97-28.57-17.47-39.7737.2221.94
Free Cash Flow-86.32-84.92-117.42-69.41-76.93-99.86

Revenue breakdown

In Vitro & In Vivo Diagnostic Substances2024: 57.88M 2025: 67.67M
United States2024: 57.88M 2025: 67.67M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3033.07%44.4M134.2M4.36M
2026-10-1533.18%44.4M133.9M4.32M
2026-09-3033.68%45.1M133.9M3.93M
2026-09-1534.85%46.7M133.9M4.20M
2026-08-3132.80%43.9M133.9M4.79M
2026-08-1433.51%44.9M133.9M5.26M
2026-07-3132.86%44.0M133.9M5.67M
2026-07-1534.29%45.8M133.5M6.89M
2026-06-3036.86%49.2M133.5M6.49M
2026-06-1537.69%50.3M133.5M5.97M
2026-05-2936.62%48.5M132.5M5.70M
2026-05-1539.19%51.8M132.3M5.34M
2026-04-3038.92%43.5M111.9M4.83M
2026-04-1534.63%38.8M112.1M4.35M
2026-03-3134.75%38.9M112.1M4.88M
2026-03-1335.19%39.4M112.1M4.78M
2026-02-2739.53%44.3M112.1M4.55M
2026-02-1341.19%45.3M109.9M4.89M
2026-01-3041.24%45.3M109.9M6.00M
2026-01-1538.72%42.6M109.9M6.75M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call3.006.809.900.0013.6810.000.000.969-0.0440.001
call4.006.008.900.0010.6480.000.000.959-0.0440.002
call5.005.107.900.008.6530.000.000.949-0.0430.002
call6.003.507.300.008.2390.000.000.936-0.0420.002
call7.002.555.504.455.0260.002.000.920-0.0400.003
call8.001.955.305.905.7495.000.000.899-0.0370.003
call9.001.802.802.601.96017650.000.869-0.0340.004
call10.001.102.151.501.9991780.000.816-0.0290.005
call11.000.751.150.901.33239927.000.608-0.0640.007
call12.000.000.500.421.04093059.000.410-0.0410.007
call13.000.100.200.181.0651,67617.000.242-0.0340.006
call14.000.050.100.091.03665923.000.119-0.0210.004
call15.000.000.100.051.2746941.000.101-0.0230.003
call16.000.000.350.041.4862442.000.090-0.0240.003
call17.000.000.100.051.4454550.000.049-0.0140.002
call18.000.001.350.101.85237.000.000.076-0.0270.003
call19.000.000.200.142.01316.000.000.071-0.0280.002
call20.000.000.050.051.86734.000.000.040-0.0150.002
put3.000.001.350.006.2280.000.00-0.031-0.0440.001
put4.000.001.350.004.9720.000.00-0.041-0.0440.002
put5.000.001.350.004.0270.000.00-0.051-0.0430.002
put6.000.001.200.003.2630.000.00-0.064-0.0410.002
put7.000.001.250.052.6161.000.00-0.080-0.0390.003
put8.000.001.250.152.04821.000.00-0.101-0.0360.003
put9.000.001.000.151.5314970.00-0.131-0.0330.004
put10.000.100.200.141.04165952.00-0.184-0.0280.005
put11.000.351.200.351.8031,03612.00-0.392-0.0630.007
put12.000.651.050.930.99983611.00-0.590-0.0390.007
put13.001.452.201.511.6673150.00-0.758-0.0320.006
put14.000.803.202.202.0344040.00-0.881-0.0190.004
put15.002.804.303.712.5115.006.00-0.899-0.0210.003
put16.002.556.704.904.8682.000.00-0.910-0.0220.003
put17.004.206.905.903.9881.000.00-0.918-0.0240.003
put18.004.708.500.005.1110.000.00-0.924-0.0250.003
put19.006.308.907.904.4561.000.00-0.929-0.0250.002
put20.006.7010.509.005.55210.000.00-0.959-0.0140.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-283Initial statement of beneficial ownership of securities2026-10-26SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-09-048-KCurrent report2026-09-04SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-20144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07SCHEDULE 13GSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-244Statement of changes in beneficial ownership of securities2026-07-22SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-02144Filing for proposed sale of securities under Rule 144.SEC
2026-06-158-KCurrent report2026-06-13SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-108-KCurrent report2026-06-09SEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100107.91K1
2026-100023.17K1
2026-090000
2026-0800286.82K2
2026-0700219.75K3
2026-060000
2026-050000
2026-040000
2026-030025.05K2
2026-020000
2026-011.40M1772.14K7
2025-1200836.38K1
2025-110000

Institutional holders

Manager% owned
ARK Investment Management LLC12.08%
BlackRock, Inc.11.03%
STATE STREET CORP6.61%
VANGUARD PORTFOLIO MANAGEMENT LLC5.25%
D. E. Shaw & Co., Inc.4.61%
VANGUARD CAPITAL MANAGEMENT LLC4.31%
TWO SIGMA INVESTMENTS, LP3.75%
FMR LLC3.35%
RA CAPITAL MANAGEMENT, L.P.3.24%
REGENERON PHARMACEUTICALS, INC.2.64%

Funds

Fund% owned
ARK Innovation ETF7.15%
State Street(R) SPDR(R) S&P(R) Biotech ETF4.12%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.07%
iShares Russell 2000 ETF2.52%
VANGUARD SMALL-CAP INDEX FUND2.22%
ARK Genomic Revolution ETF1.91%
Select Biotechnology Portfolio1.37%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.29%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
Fidelity Small Cap Index Fund1.06%

OakChart. NTLA. Cached 15 minutes.